Bactericidal activity and mechanism of action of azd5847, a novel oxazolidinone for treatment of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 495-502

  Balasubramanian, V ^a   Solapure, S ^a   Iyer, H ^a   Ghosh, A ^a   Sharma, S ^a   Kaur, P ^a   Deepthi, R ^a   Subbulakshmi, V ^a   Ramya, V ^a   Ramachandran, V ^a   Balganesh, M ^a   Wright, L ^a   Melnick, D ^a   Butler, S L ^a   Sambandamurthy, V K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5847; CERULENIN; CHLORAMPHENICOL; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; IC 50; IN VITRO STUDY; ISOMERIZATION; LIMIT OF QUANTITATION; MACROMOLECULE; MACROPHAGE; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; NONHUMAN; PH; PRIORITY JOURNAL; RIBOSOME SUBUNIT; SEQUENCE ANALYSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS;

EID: 84891550770     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01903-13     Document Type: Article

References (26)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ global-report/en/.
2. Dye C, Williams BG. 2010. The population dynamics and control of TB. Science 328:856-861. http://dx.doi.org/10.1126/science.1185449.
3. Sacks LV, Behrman RE. 2008. Developing new drugs for the treatment of drug resistant tuberculosis: A regulatory perspective. Tuberculosis (Edinb.) 88(Suppl 1):S93-S100. http://dx.doi.org/10.1016/S1472-9792(08)70040-4.
4. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. 2009. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 9:153-161. http://dx.doi.org/10.1016/S1473-3099(09)70041-6.
5. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One 4:e6914. http://dx.doi.org/10.1371/journal.pone.0006914.
6. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ. 2007. Combined therapy for tuberculosis and HIV-1: The challenge for drug discovery. Drug Discov. Today 12:980-989. http://dx.doi.org/10.1016/j.drudis.2007 .08.001.
7. Jones D. 2013. Tuberculosis success. Nat. Rev. Drug Discov. 12:175-176. http://dx.doi.org/10.1038/nrd3957.
8. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185. http://dx.doi.org/10.1093/jac/dki148.
9. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-192. http://dx.doi.org/10.1378/chest. 07-1988.
10. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. 2012. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40:1430- 1442. http://dx.doi.org/10.1183/09031936.00022912.
11. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon H-S, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee J-K, Lee D, Kim CT, Dartois V, Park S-K, Cho S-N, Barry CE. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
12. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C, TBNET Study Group. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug- resistant tuberculosis. Eur. Respir. J. 34:387-393. http://dx.doi.org/10.1183/09031936.00009509.
13. Carroll MW, Choi H, Min S, Hwang S, Park H, Song T, Park Y, Jeon HS, Goldfeder LC, Via LE, Lebron J, Jin B, Cai Y, Barry CE, III, Lee M. 2012. Rhabdomyolysis in a patient treated with linezolid for extensively drug resistant (XDR) tuberculosis. Clin. Infect. Dis. 54:1624-1627. http://dx.doi.org/10.1093/cid/cis293.
14. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751. http://dx.doi.org/10.1086/655471.
15. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. http://dx.doi.org/10. 1128/AAC.47.7.2118-2124.2003.
16. Shirude PS, Madhavapeddi P, Tucker JA, Murugan K, Patil V, Basavarajappa H, Raichurkar AV, Humnabadkar V, Hussein S, Sharma S, Ramya VK, Narayan CB, Balganesh TS, Sambandamurthy VK. 2013. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. ACS Chem. Biol. 8:519-523. http://dx.doi.org/10.1021/cb300510w.
17. Solapure S, Dinesh N, Shandil R, Ramachandran V, Sharma S, Bhattacharjee D, Ganguly S, Reddy J, Ahuja V, Panduga V, Parab M, Vishwas KG, Kumar N, Balganesh M, Balasubramanian V. 2013. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/ nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:2506-2510. http://dx.doi.org/10.1128/AAC.00023-13.
18. Czock D, Keller F. 2007. Mechanism-based pharmacokineticpharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34:727-751. http://dx.doi.org/10.1007/s10928-007-9069-x.
19. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70. http://dx.doi.org/10.1111/j.1749-6632. 2011.06330.x.
20. Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S. 2012. rplC T460C identified as a dominant mutation in linezolid resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. 56:2743-2745. http://dx.doi.org/10.1128/AAC.06227-11.
21. Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Seftonet V. 2004. AZD2563, a novel oxazolidinone: definition of antibacterial spectrumassessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin. Microbiol. Infect. 10:247-254. http://dx.doi.org/10.1111/j.1198-743X.2004.00770.x.
22. Rohde KH, Veiga DF, Caldwell S, Balázsi G, Russell DG. 2012. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog. 8:e1002769. http://dx.doi.org/10.1371/journal.ppat.1002769.
23. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. 2012. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov. 11: 171-172. http://dx.doi.org/10.1038/nrd3694.
24. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS. 2007. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 26:393-402. http://dx.doi.org/10.1016/j.molcel.2007.04.005.
25. Hillemann D, Rusch-Gerdes S, Richter E. 2008. In vitro-selected linezolidresistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother. 52:800-801. http://dx.doi.org/10.1128/AAC.01189-07.
26. Cox H, Ford N. 2012. Linezolid for the treatment of complicated drugresistant tuberculosis: A systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 16:447-454. http://dx.doi.org/10.5588/ijtld.11.0451.